Co-Authors
This is a "connection" page, showing publications co-authored by MILIND JAVLE and LAWRENCE KWONG.
Connection Strength
1.325
-
Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. JCO Precis Oncol. 2024 Mar; 8:e2300544.
Score: 0.238
-
CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon. JCI Insight. 2024 Jan 23; 9(2).
Score: 0.236
-
The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022 02; 75(2):297-308.
Score: 0.204
-
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep. 2020 12 16; 10(1):22087.
Score: 0.190
-
Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Curr Treat Options Oncol. 2016 11; 17(11):58.
Score: 0.143
-
Utilizing Patient-derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. Clin Cancer Res. 2024 Nov 08.
Score: 0.062
-
KRAS Allelic Variants in Biliary Tract Cancers. JAMA Netw Open. 2024 May 01; 7(5):e249840.
Score: 0.060
-
Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024 02; 80(2):322-334.
Score: 0.058
-
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol. 2022 02; 6:e2100197.
Score: 0.051
-
Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. JCO Precis Oncol. 2020; 4.
Score: 0.046
-
Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016 Dec; 7(6):819-827.
Score: 0.036